FDA Conditionally Approves QYLEKI™ as Brand Name for Quoin's Lead Drug QRX003
QNRX sits 28% above its 52-week low of $4.1 on light trading volume (0.2× avg).
Summary
The FDA has conditionally approved QYLEKI™ as the proposed brand name for Quoin Pharmaceuticals' lead drug candidate, QRX003, for Netherton Syndrome. This marks another positive regulatory step for the micro-cap biotech, following recent Orphan Drug Designation in Japan and positive clinical results for QRX003. While not marketing approval, it signals continued progress towards commercialization for a product targeting an unmet medical need. A pivotal Phase 3 study is expected in H2 2026, with an NDA filing anticipated in 2027.
At the time of this announcement, QNRX was trading at $5.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.6M. The 52-week trading range was $4.10 to $41.80. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.